Sodium-glucose cotransporter-2 inhibitors improve liver enzymes in patients with co-existing non-alcoholic fatty liver disease: a systematic review and meta-analysis

INTRODUCTION: Non-alcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis, inflammation, and fibrosis. While sodium-glucose cotransporter-2 (SGLT-2) inhibitors have been established to improve glycaemic control in type-2 diabetes mellitus (T2DM), evidence of the beneficial effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Amjad, Waseem, Malik, Adnan, Qureshi, Waqas, Dennis, Brittany, Mumtaz, Mirrah, Haider, Rabbia, Jamal, Shakeel, Jaura, Faisal, Ahmed, Aijaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2022
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743335/
https://www.ncbi.nlm.nih.gov/pubmed/36514450
http://dx.doi.org/10.5114/pg.2021.112365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743335/
https://www.ncbi.nlm.nih.gov/pubmed/36514450
http://dx.doi.org/10.5114/pg.2021.112365

Ejemplares similares